Zobrazeno 1 - 10
of 70
pro vyhledávání: '"Bradley M. Turner"'
Autor:
Danielle E. Desa, Robert L. Strawderman, Wencheng Wu, Robert L. Hill, Marcel Smid, J. W. M. Martens, Bradley M. Turner, Edward B. Brown
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-14 (2020)
Abstract Background Metastases are the leading cause of breast cancer-related deaths. The tumor microenvironment impacts cancer progression and metastatic ability. Fibrillar collagen, a major extracellular matrix component, can be studied using the l
Externí odkaz:
https://doaj.org/article/fdbdba99c78b4fe0a6cbb731ab32a392
Publikováno v:
Cancers, Vol 15, Iss 3, p 808 (2023)
The 1983 discovery of a mouse monoclonal antibody—the Ki-67 antibody—that recognized a nuclear antigen present only in proliferating cells represented a seminal discovery for the pathologic assessment of cellular proliferation in breast cancer an
Externí odkaz:
https://doaj.org/article/ff16846a23a648939b15dba30638fb90
Autor:
Bradley M. Turner, Brian S. Finkelman, David G. Hicks, Numbere Numbereye, Ioana Moisini, Ajay Dhakal, Kristin Skinner, Mary Ann G. Sanders, Xi Wang, Michelle Shayne, Linda Schiffhauer, Hani Katerji, Huina Zhang
Publikováno v:
Cancers, Vol 15, Iss 3, p 903 (2023)
Introduction: Multigene genomic profiling has become the standard of care in the clinical risk-assessment and risk-stratification of ER+, HER2− breast cancer (BC) patients, with Oncotype DX® (ODX) emerging as the genomic profile test with the most
Externí odkaz:
https://doaj.org/article/21deb6515ff14842be610ec68fc190a3
Publikováno v:
Human Pathology Reports, Vol 26, Iss , Pp 300570- (2021)
Vascular lesions are uncommonly encountered in the breast and they represent a spectrum of benign, atypical and malignant entities. The mammary angiosarcomas can be primary arising de novo, or most frequently secondary to prior radiation therapy for
Externí odkaz:
https://doaj.org/article/2b149b1869d4446eb3f23fd46d2fdd4b
Publikováno v:
Human Pathology Reports, Vol 26, Iss , Pp 300574- (2021)
As breast cancer treatment options continue to evolve, biomarker and multigene assay testing are now considered a standard part of the clinical evaluation of estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER-2) negative b
Externí odkaz:
https://doaj.org/article/8d52553126714d96a4a28788a81db70e
Autor:
Bradley M. Turner, Mary Ann Gimenez‐Sanders, Armen Soukiazian, Andrea C. Breaux, Kristin Skinner, Michelle Shayne, Nyrie Soukiazian, Marilyn Ling, David G. Hicks
Publikováno v:
Cancer Medicine, Vol 8, Iss 9, Pp 4176-4188 (2019)
Abstract The skyrocketing cost of health‐care demands that we question when to use multigene assay testing in the planning of treatment for breast cancer patients. A previously published algorithmic model gave recommendations for which cases to sen
Externí odkaz:
https://doaj.org/article/b1be917011db4b41aedf1fbf7d9e2b92
Autor:
Danielle E. Desa, Wencheng Wu, Robert M. Brown, Edward B. Brown, Robert L. Hill, Bradley M. Turner
Publikováno v:
Cancers, Vol 14, Iss 4, p 857 (2022)
Breast cancer is the most common invasive cancer in women, with most deaths attributed to metastases. Neoadjuvant chemotherapy (NACT) may be prescribed prior to surgical removal of the tumor for subsets of breast cancer patients but can have diverse
Externí odkaz:
https://doaj.org/article/9896130770ed478cae3a81fb18c9d4c6
Autor:
Cansu Karakas, Haley Tyburski, Bradley M Turner, Xi Wang, Linda M Schiffhauer, Hani Katerji, David G Hicks, Huina Zhang
Publikováno v:
American Journal of Clinical Pathology. 159:484-491
Objectives We assessed the interobserver and interantibody reproducibility of HER2 immunohistochemical scoring in an enriched HER2-low–expressing breast cancer cohort. Methods A total of 114 breast cancer specimens were stained by HercepTest (Agile
Autor:
Huina Zhang, Cansu Karakas, Haley Tyburski, Bradley M Turner, Yan Peng, Xi Wang, Hani Katerji, Linda Schiffhauer, David G Hicks
Publikováno v:
Seminars in Diagnostic Pathology. 39:305-312
In light of the significant clinical benefits of novel HER2-targeting antibody-drug conjugates in advanced HER2-low expressing breast cancers in recent phases I and III clinical trials, particularly trastuzumab-deruxtecan (T-Dxd), the new "HER2-low"
Publikováno v:
Modern Pathology. 35:1075-1082
Recently, clinical trials have demonstrated promising efficacy for novel HER2-targeted therapies in HER2-low breast cancers, raising the prospect of including a HER2-low category (immunohistochemical [IHC] score of 1+, or 2+ with non-amplified in-sit